<DOC>
	<DOCNO>NCT00355667</DOCNO>
	<brief_summary>The purpose study compare therapeutic effect furosemide , short-acting loop diuretic , azosemide , long-acting one , patient heart failure , test hypothesis long-acting diuretic superior short-acting type heart failure .</brief_summary>
	<brief_title>Comparison Long- Short-acting Diuretics Congestive Heart Failure</brief_title>
	<detailed_description>The mortality morbidity heart failure still high despite emerge evidence show beneficial effect ACE inhibitor , beta-blocker , ARB , aldosterone receptor antagonist . Diuretics prescribed heart failure patient attenuate symptom due fluid retention , diuretic recommend essential medicine patient heart failure symptom and/or fluid retention . However , effect long-term administration diuretic morbidity mortality adequately assess prospective clinical study , retrospective analysis necessarily indicate diuretic-induced improvement mortality . McCurley et al demonstrated adverse effect furosemide tachycardia-induced heart failure model ( J Am Coll Cardiol 2004 ; 44 : 1301-1307 ) . Yoshida et al . demonstrate administration furosemide improve mortality rate , administration azosemide , long-acting loop diuretic , improve mortality rate hypertensive heart failure model ( Cardiovasc Res 2005 ; 68 : 118-127 ) . If effect mortality and/or morbidity heart failure patient different among class diuretic , choose class provide good prognosis . Thus , design multicenter prospective study , J-Melodic ( Japanese Multicenter Evaluation LOng- versus short-acting Diuretics In Congestive heart failure ) obtain clinical evidence effect diuretic heart failure . Comparison : Congestive heart failure patient match follow condition recruit : ( 1 ) clinical diagnosis heart failure base slight modification Framingham criterion within 6 month entry , ( 2 ) twenty year old , ( 3 ) NYHA II III , ( 4 ) loop diuretic ( ) ( ) administer currently , ( 5 ) change baseline therapy symptom heart failure within month . After screen eligibility obtain write informed consent , patient randomize either azosemide furosemide treatment 1:1 ratio . In arm , patient treat standard therapy include digitalis , mineralocorticoid receptor blocker , ACE inhibitor , ARB , beta-blockers , calcium channel blocker . Patients discontinue take previous loop diuretic ( ) directly roll one two arm either azosemide 30-60 mg/day furosemide 20-40 mg/day , without placebo run-in period . The dose diuretic appropriately adjust accord symptoms patient , patient maintain rest study . Thereafter , patient review every 2 8 week . The planned minimum follow-up period patient 2 year , electrocardiography , chest X-ray blood sample conduct study entry every 12 month randomization . The primary outcome composite cardiovascular death unplanned admission hospital congestive heart failure . The secondary outcome list follow : cause mortality ; worsen symptom [ define either decrease ( 1 ) 1 Mets SAS questionnaire score increase ( 2 ) I class NYHA functional class least 3 month compare baseline ] ; increase brain natriuretic peptide ( BNP ) 30 % value randomization patient BNP le 200 pg/ml randomization ; unplanned admission hospital congestive heart failure , need modification treatment heart failure ( change oral medicine least one month addition intravenous drug ( ) least 4 hour ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Azosemide</mesh_term>
	<mesh_term>Sulfanilamides</mesh_term>
	<criteria>Clinical diagnosis heart failure base slight modification Framingham criterion previously describe within 6 month entry Current status heart failure NYHA II III . Currently , loop diuretic ( ) ( ) administer . No change baseline therapy symptom heart failure within month Current symptomatic hypotension Hypertension control satisfaction investigator Hemodynamically significant ( investigator opinion ) LV outflow tract obstruction ( due either aortic stenosis ventricular hypertrophy ) Acute coronary syndrome Primary pulmonary hypertension pulmonary hypertension due LV dysfunction Serious cerebrovascular disease Acute myocardial infarction within last 3 month Patients require intravenous inotropes Cerebrovascular accident within last 3 month Percutaneous coronary intervention open heart surgery within last 3 month On wait list percutaneous coronary intervention open heart surgery Serum creatinine &gt; 2.5 mg/dl Serious liver disease Any change cardiovascular drug therapy within month prior randomization History chronic obstructive pulmonary disease restrictive lung disease Diabetes mellitus well control ( fast blood glucose &gt; 200 mg/dl„ÄÅHbA1c &gt; 8 % ) Any lifethreatening acute disease Patients implantable cardiac defibrillator Other disease likely cause death serious disability period study Patients unable walk without personal aid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>diuretic</keyword>
	<keyword>furosemide</keyword>
	<keyword>azosemide</keyword>
	<keyword>congestive heart failure</keyword>
</DOC>